Regulation of faecal microbiota transplant

Faecal microbiota transplantation (FMT) is recognised as an emerging treatment for recurrent Clostridium difficile infections in patients where antibiotic and other lines of treatment have failed.

FMT is outside the scope of the Human Tissue (Quality and Safety for Human Application) Regulations, 2007 (as amended) and is not regulated by the HTA.

Establishments seeking to perform FMT should contact the MHRA Medicines Borderline Section for further advice.

Regulating human embryonic stem cell lines for human application

This is the joint position from the Human Tissue Authority (HTA), Human Fertilisation and Embryology Authority (HFEA) and Medicines and Healthcare products Regulatory Agency (MHRA). The aim of regulating human embryonic stem cells (hESCs) is to ensure that the highest standards are met from their derivation in the laboratory through to their clinical application.